Stock Groups

Novartis says U.S. court upholds Gilenya patent -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILEPHOTO: The Novartis logo, the Swiss drugmaker Novartis is seen in its facility in Stein, Switzerland on October 23rd 2017. REUTERS/Arnd Wiegmann

ZURICH, (Reuters) – Novartis AG announced Tuesday that a U.S. appeals court upheld the legality of a dosage-regime patent for the multiple sclerosis treatment Gilenya. The permanent injunction against HEC Pharma in China will remain in effect until the patent expires 2027.

The statement by the Swiss drugmaker stated that the decision “confirms the validity and allows for the injunction” and added that it expects no generic Gilenya versions to be available in the U.S. Market in at least two years.

HEC was rejected Monday by the U.S. Court of Appeals Federal Circuit. The panel separated and rejected HEC’s arguments that the patent did not contain a written description. It threw out the company’s attempts to make a generic Gilenya product before its patent expires.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, futures, indexes or Forex. The prices of Forex and CFDs are provided by market makers and are therefore not necessarily accurate. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]